Канал: Cytel

Cytel HEOR & RWE peer reviewed publications

Cytel HEOR & RWE peer reviewed publications

Cytel Together We Push Boundaries

Cytel Together We Push Boundaries

Cytel LiveSLR™

Cytel LiveSLR™

Cytel - Designed for Results

Cytel - Designed for Results

My Cytel Federated Single Sign On - Cytel Portal

My Cytel Federated Single Sign On - Cytel Portal

Solara - Decide Together

Solara - Decide Together

Solara - Communicate Trade Offs

Solara - Communicate Trade Offs

Introducing Solara

Introducing Solara

Solara - Thoroughly Explore

Solara - Thoroughly Explore

Head-to-Head Comparisons using Real-World Data

Head-to-Head Comparisons using Real-World Data

Introduction to Population Enrichment Trial Designs

Introduction to Population Enrichment Trial Designs

Head to Head Comparisons Using Real World Data

Head to Head Comparisons Using Real World Data

Practical Model-based Approaches for Phase 1 Oncology Trials

Practical Model-based Approaches for Phase 1 Oncology Trials

Synthetic Controls In Clinical Trials

Synthetic Controls In Clinical Trials

Group Sequential Designs and Sample Size Re-estimation - Modern Uses

Group Sequential Designs and Sample Size Re-estimation - Modern Uses

Bayesian Approaches to Address Clinical Development Challenges for COVID-19 Vaccine/Drugs/Devices

Bayesian Approaches to Address Clinical Development Challenges for COVID-19 Vaccine/Drugs/Devices

Estimands in Oncology - A Virtual Panel Discussion

Estimands in Oncology - A Virtual Panel Discussion

Innovative Drug Development at a Glance - The Concepts, The Vision, & The Factors to Consider

Innovative Drug Development at a Glance - The Concepts, The Vision, & The Factors to Consider

Study Designs for Oncology and Rare Diseases

Study Designs for Oncology and Rare Diseases

Refocus your Enrollment to the Subpopulation of Interest with ENRICH

Refocus your Enrollment to the Subpopulation of Interest with ENRICH

Optimizing Market Access for Medical Devices

Optimizing Market Access for Medical Devices

Conducting Sample Size Reassessment with Time-to-event Endpoints

Conducting Sample Size Reassessment with Time-to-event Endpoints

New Opportunities & Implications for the Future of Drug Development in Emerging Economies

New Opportunities & Implications for the Future of Drug Development in Emerging Economies

Phase 2 Dose-finding Studies with MCP and Modelling Techniques

Phase 2 Dose-finding Studies with MCP and Modelling Techniques

A Clinician's Perspective on Cancer Drug Development

A Clinician's Perspective on Cancer Drug Development

COVID-19 Trials, Designs, and Tools for Promising Results

COVID-19 Trials, Designs, and Tools for Promising Results

Phase 1 Dose Escalation Trials with ESCALATE

Phase 1 Dose Escalation Trials with ESCALATE

Transparent Machine Learning

Transparent Machine Learning

Ongoing Trials During COVID-19:Quantitative Strategies and Methodological Aspects

Ongoing Trials During COVID-19:Quantitative Strategies and Methodological Aspects

Adaptive Umbrella Trials Using MAMS Module

Adaptive Umbrella Trials Using MAMS Module

Key Design Considerations for Basket and Umbrella Trials

Key Design Considerations for Basket and Umbrella Trials

Designing Event Based Studies: Reduce Sample Size and Increase Predictability

Designing Event Based Studies: Reduce Sample Size and Increase Predictability

Harness Patient Reported Outcomes

Harness Patient Reported Outcomes

Adaptive Trial Designs - Introduction for Non-Statisticians

Adaptive Trial Designs - Introduction for Non-Statisticians

Resolving Prior-Data Conflict

Resolving Prior-Data Conflict

Tests for Multiple Endpoints, Part 2 of 3

Tests for Multiple Endpoints, Part 2 of 3

Saddle Point Approximation, Part 3 of 3

Saddle Point Approximation, Part 3 of 3

Unconditional Exact Test for Two Binomials, Part 1 of 3

Unconditional Exact Test for Two Binomials, Part 1 of 3

Cytel Strategic Consulting: A Unique Collaboration

Cytel Strategic Consulting: A Unique Collaboration

How We Identify Solutions for Our Customers

How We Identify Solutions for Our Customers

Optimizing Drug Development with Model-Informed Decision Making

Optimizing Drug Development with Model-Informed Decision Making

Preparing for Regulatory Interactions When Planning Adaptive Designs with Interim Analyses

Preparing for Regulatory Interactions When Planning Adaptive Designs with Interim Analyses

Adaptive Dose-Finding Designs: Improving Development Strategies

Adaptive Dose-Finding Designs: Improving Development Strategies

It's All About the Data: Cytel Data-Driven Clinical Services

It's All About the Data: Cytel Data-Driven Clinical Services

Cytel Year's End Tribute

Cytel Year's End Tribute

Webinar: Trial Design Concept for a Confirmatory Basket Trial - Dr. Robert Beckman

Webinar: Trial Design Concept for a Confirmatory Basket Trial - Dr. Robert Beckman

Bayesian Optimisation of Enrichment Designs - Thomas Burnett

Bayesian Optimisation of Enrichment Designs - Thomas Burnett

Planning and Optimizing Phase II/III Programs for Trials with Multiple Comparisons - Meinhard Kieser

Planning and Optimizing Phase II/III Programs for Trials with Multiple Comparisons - Meinhard Kieser

Group Sequential versus P-value Combination Approaches for Adaptive Designs - Cyrus Mehta

Group Sequential versus P-value Combination Approaches for Adaptive Designs - Cyrus Mehta

Selection Bias from Picking Treatments Only with Phase 2 Trials - Simon Kirby

Selection Bias from Picking Treatments Only with Phase 2 Trials - Simon Kirby

70 Years Old and Still Here: The Randomized Clinical Trial and its Critics - Stephen Senn

70 Years Old and Still Here: The Randomized Clinical Trial and its Critics - Stephen Senn

New In East® 6.5: Introduction to the MCP Mod and Population Enrichment modules

New In East® 6.5: Introduction to the MCP Mod and Population Enrichment modules

New in East 6.5: MCP Mod, Population Enrichment & Program-Level Design

New in East 6.5: MCP Mod, Population Enrichment & Program-Level Design

Introduction to ACES: Access Control Execution System

Introduction to ACES: Access Control Execution System

Why Choose a Cytel Career? With JT Wang

Why Choose a Cytel Career? With JT Wang

Why Choose a Cytel Career? With Lesli Weissman

Why Choose a Cytel Career? With Lesli Weissman

Why Choose a Cytel Career? With Sachin Sobale

Why Choose a Cytel Career? With Sachin Sobale

Why Choose a Cytel Career? With Teri Stokes

Why Choose a Cytel Career? With Teri Stokes

ACES Demonstration - Chapter 3: Audit Trail & Conclusion

ACES Demonstration - Chapter 3: Audit Trail & Conclusion

ACES Demonstration - Chapter 2 Sponsor & Admin Access

ACES Demonstration - Chapter 2 Sponsor & Admin Access

ACES Demonstration - Chapter 1: Overview and DMC Access

ACES Demonstration - Chapter 1: Overview and DMC Access

Decisions for Your Next Clinical Trial WebEx

Decisions for Your Next Clinical Trial WebEx

Ready to Adopt the Regulatory CDISC Standards for Next Clinical Trial?

Ready to Adopt the Regulatory CDISC Standards for Next Clinical Trial?

30th Anniversary Global Celebrations

30th Anniversary Global Celebrations

Cytel Core Values - A Deeper Dive with the Company Founders

Cytel Core Values - A Deeper Dive with the Company Founders

The Core Values of Cytel as Told by Co-Founders Cyrus Mehta and Nitin Patel

The Core Values of Cytel as Told by Co-Founders Cyrus Mehta and Nitin Patel

Asking the Right Questions of Your Data: Experiences with Model-informed Development Approaches

Asking the Right Questions of Your Data: Experiences with Model-informed Development Approaches

David Delamaire, Senior Manager Recruiting at Cytel is Hiring!

David Delamaire, Senior Manager Recruiting at Cytel is Hiring!

Multi-Arm Multi-Stage (MAMS) module in East with Pantelis Vlachos, Ph.D & Cyrus Mehta, Ph.D

Multi-Arm Multi-Stage (MAMS) module in East with Pantelis Vlachos, Ph.D & Cyrus Mehta, Ph.D

Determining the Future Course of Your Trial with East PREDICT

Determining the Future Course of Your Trial with East PREDICT

Go / No Go Decision Making with Charles Liu

Go / No Go Decision Making with Charles Liu

Tracon Pharmaceuticals - An Innovative Enrichment Design for a Rare Cancer

Tracon Pharmaceuticals - An Innovative Enrichment Design for a Rare Cancer

Accessing the Adaptive Design Features in East® 6

Accessing the Adaptive Design Features in East® 6

Practical Challenges with S1400 Lung MAP Clinical Study - Antje Hoering, CRAB

Practical Challenges with S1400 Lung MAP Clinical Study - Antje Hoering, CRAB

The CMO/Biostatistician Connection – Driving Clinical Development Efficiency

The CMO/Biostatistician Connection – Driving Clinical Development Efficiency

East® 6.4 Webinar: Designing Single and Dual Agent Dose Escalation Trials

East® 6.4 Webinar: Designing Single and Dual Agent Dose Escalation Trials

Trial Enrollment and Events Prediction with East® 6.4 - Pantelis Vlachos

Trial Enrollment and Events Prediction with East® 6.4 - Pantelis Vlachos

SurvSim: SAS Macro for Survival Data Simulation Conditions on Covariates - Al Li

SurvSim: SAS Macro for Survival Data Simulation Conditions on Covariates - Al Li

Topics in the Estimation of Historical Control in Early Phase Oncology Trials - Lynn Navale

Topics in the Estimation of Historical Control in Early Phase Oncology Trials - Lynn Navale

Estimating the Analysis Date for Time-to-Event Study Endpoints - Todd DeVries

Estimating the Analysis Date for Time-to-Event Study Endpoints - Todd DeVries

Challenges Faced by Clinical Data Managers and Statisticians in Early Stage Oncology - Tim Connolly

Challenges Faced by Clinical Data Managers and Statisticians in Early Stage Oncology - Tim Connolly

Multi-Arm Multi-Stage (MAMS) Methods for Confirmatory Trials in East® - Pantelis Vlachos

Multi-Arm Multi-Stage (MAMS) Methods for Confirmatory Trials in East® - Pantelis Vlachos

Single and Dual Agent Oncology Dose-Escalation Designs in East® 6.4 - Pantelis Vlachos

Single and Dual Agent Oncology Dose-Escalation Designs in East® 6.4 - Pantelis Vlachos

Introduction to East® Clinical Trial Design Software - Pantelis Vlachos

Introduction to East® Clinical Trial Design Software - Pantelis Vlachos

New Developments in East: Designing MAMS Clinical Trials - Cyrus Mehta, Cytel

New Developments in East: Designing MAMS Clinical Trials - Cyrus Mehta, Cytel

Determining the Future Course of Your Trial - Yannis Jemiai, Cytel

Determining the Future Course of Your Trial - Yannis Jemiai, Cytel

Decision Making in Early Clinical Development - Paul Frewer, AstraZeneca

Decision Making in Early Clinical Development - Paul Frewer, AstraZeneca

Blinded SSR in Early Phase Biosimilars Studies - Francois Beckers, Merck KGaA

Blinded SSR in Early Phase Biosimilars Studies - Francois Beckers, Merck KGaA

A Model-Free Approach for a Combination Phase 1 Trial - Adrian Mander, MRC

A Model-Free Approach for a Combination Phase 1 Trial - Adrian Mander, MRC

Bayesian-Based Dose Escalation Clinical Trial Designs - Pantelis Vlachos, Cytel

Bayesian-Based Dose Escalation Clinical Trial Designs - Pantelis Vlachos, Cytel

Subgroup Analyses in Early Phase Clinical Trials - Bjorn Bornkamp, Novartis

Subgroup Analyses in Early Phase Clinical Trials - Bjorn Bornkamp, Novartis

Adjusting Overall Survival for Treatment Switch - Claire Watkins, Clarostat

Adjusting Overall Survival for Treatment Switch - Claire Watkins, Clarostat

Adaptive Financing: Aligning Development Finance Strategy with Trial Design

Adaptive Financing: Aligning Development Finance Strategy with Trial Design

A Competitive Alternative to Model-based Dose Escalation Procedures

A Competitive Alternative to Model-based Dose Escalation Procedures

Model-based Designs in Oncology Dose-finding Studies

Model-based Designs in Oncology Dose-finding Studies

Decision Making in an Early Oncology Event Study

Decision Making in an Early Oncology Event Study

Dose Escalation Design with Consideration of Late Onset Toxicity

Dose Escalation Design with Consideration of Late Onset Toxicity

Simulation-Guided Patient Enrollment Forecasting with the EnForeSys Software

Simulation-Guided Patient Enrollment Forecasting with the EnForeSys Software

James Wason: Statistical Issues in the Design of Multi-Arm Multi-Stage (MAMS) trials.

James Wason: Statistical Issues in the Design of Multi-Arm Multi-Stage (MAMS) trials.

Conceiving and Implementing Innovations in Clinical Data Management

Conceiving and Implementing Innovations in Clinical Data Management

Statistical and Operational Challenges of VALOR: Adaptive Phase 3 Oncology Trial

Statistical and Operational Challenges of VALOR: Adaptive Phase 3 Oncology Trial

Statistical Planning and Execution of Large CV Outcomes Trials

Statistical Planning and Execution of Large CV Outcomes Trials

Identifying the Path Forward: Using Simulation for Adaptive Designs in Survival Studies

Identifying the Path Forward: Using Simulation for Adaptive Designs in Survival Studies

Alternative Methods to Designing Clinical Trials in Phase 1 Oncology

Alternative Methods to Designing Clinical Trials in Phase 1 Oncology

A Bayesian Industry Approach to Phase 1 Combination Trials in Oncology - Satrajit Roychoudhury

A Bayesian Industry Approach to Phase 1 Combination Trials in Oncology - Satrajit Roychoudhury

Adaptive Dose Finding Using Toxicity Probability Intervals - Neby Bekele

Adaptive Dose Finding Using Toxicity Probability Intervals - Neby Bekele

Designing Proof-of-Concept Clinical Trials - Ashwin Gollerkeri, M.D., Pfizer

Designing Proof-of-Concept Clinical Trials - Ashwin Gollerkeri, M.D., Pfizer

Blinded Adaptations, Permutation Tests, and T-tests - Michael Proschan

Blinded Adaptations, Permutation Tests, and T-tests - Michael Proschan

Case Studies of Phase 2 Adaptive Dose-Finding Trials - Jim Bolognese

Case Studies of Phase 2 Adaptive Dose-Finding Trials - Jim Bolognese

Moving Beyond the Comfort Zone in Practicing Translational Statistics - LJ Wei

Moving Beyond the Comfort Zone in Practicing Translational Statistics - LJ Wei

DIA / Cytel Webinar: From Clinic to CFO - Adaptive Trials and Financial Decision-Making

DIA / Cytel Webinar: From Clinic to CFO - Adaptive Trials and Financial Decision-Making

Predicting the Future Course of Clinical Trial with Cytel's East PREDICT

Predicting the Future Course of Clinical Trial with Cytel's East PREDICT

Modern Dose Escalation Phase 1 Trials with East® ESCALATE

Modern Dose Escalation Phase 1 Trials with East® ESCALATE

Determining the Optimal Development Path

Determining the Optimal Development Path

Nonparametric Inference of Correlated Data: Solving Difficult Reserach Questions with StatXact 10

Nonparametric Inference of Correlated Data: Solving Difficult Reserach Questions with StatXact 10

Speeding Early Development with Simulation and Biomarkers

Speeding Early Development with Simulation and Biomarkers

Optimizing Development in Early Phase: mTPI Case Study, Bayesian Adaptive Dose Finding Trials

Optimizing Development in Early Phase: mTPI Case Study, Bayesian Adaptive Dose Finding Trials

Cytel and Medidata: Optimizing Drug Supply Strategies with Simulations

Cytel and Medidata: Optimizing Drug Supply Strategies with Simulations

Transforming Oncology Clinical Development with Adaptive Studies

Transforming Oncology Clinical Development with Adaptive Studies

Speeding Early Development with Simulation & Biomarkers

Speeding Early Development with Simulation & Biomarkers

Adaptive 2-Stage Design Supporting the Fulyzaq® Approval

Adaptive 2-Stage Design Supporting the Fulyzaq® Approval

The Phase 3 VALOR Trial: Adaptive Sample Size Re-estimation

The Phase 3 VALOR Trial: Adaptive Sample Size Re-estimation

Adaptive Trials in the Exploratory Stage: an Overview

Adaptive Trials in the Exploratory Stage: an Overview

Modern Oncology Research with Adaptive Trials

Modern Oncology Research with Adaptive Trials

When Outsourcing Stops Making Sense

When Outsourcing Stops Making Sense

East UGM 2013 - Franz Koenig, Medical University of Vienna, Statistician [Multiplicity Issues...]

East UGM 2013 - Franz Koenig, Medical University of Vienna, Statistician [Multiplicity Issues...]

East UGM 2013 - Sue Todd, University of Reading, Prof. of Medical Statistics [Phase II-III...]

East UGM 2013 - Sue Todd, University of Reading, Prof. of Medical Statistics [Phase II-III...]

East UGM 2013 - Ekkehard Glimm, Novartis Pharma Schweiz AG [Adaptive Designs, beyond p-value...]

East UGM 2013 - Ekkehard Glimm, Novartis Pharma Schweiz AG [Adaptive Designs, beyond p-value...]

East UGM 2013 - Chris Jennison - University of Bath [Designing an Adaptive Trial...]

East UGM 2013 - Chris Jennison - University of Bath [Designing an Adaptive Trial...]

Accelerating Early Stage Develpment with Simulation and Biomarkers

Accelerating Early Stage Develpment with Simulation and Biomarkers

Streamlining Clinical Trial Designs with Cytel's New East version 6 Software

Streamlining Clinical Trial Designs with Cytel's New East version 6 Software